FDA panel backs interleukin-2.
Culliton
B J
BJ
D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D013727:Terminal Care; D014481:United States; D014486:United States Food and Drug Administration
D007376:Interleukin-2